ESMO 2014: Exhibiting Companies

Agendia, Inc.

Agendia is a leading molecular diagnostic company that develops and markets paraffin-embedded tissue based genomic diagnostic products which help support physicians with their complex treatment decisions. The Agendia Breast Cancer Test Suite was developed using unbiased gene selection, analysing the complete human genome, ensuring reliable, definitive results for cancer patients. For more information about MammaPrint®, BluePrint® or TargetPrint® visit the company website.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Angelini

THE ANGELINI GROUP

Angelini is leader in the healthcare and wellbeing market in the pharmaceutical and mass-market sectors. In the Pharmaceutical sector, Angelini focuses on pain relief, inflammation, CNS, cold & flu, oral care & sore throat, gynaecology, disinfection. Angelini is one of the top pharmaceutical companies in Italy by sales volume, with the highest growing rate for prescription market and a leading company in the self-medication sector. The group employs about 4.000  people. Consolidated turnover in 2013 was about 1.400 million €

Astellas Pharma Europe Ltd

In 2006, Astellas made an enduring commitment to join the fight against cancer. Since then, we have built a robust global oncology R&D network and established collaborations with key organisations at the forefront of cancer research. Our goal is simple – to become a worldwide leader in the field of oncology. Our ambition is bold – to significantly advance treatment of the disease. Through intense focus on the most promising new candidates and technologies, Astellas is now developing a blossoming cancer drugs portfolio and unique pipeline.

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Barrington James

Barrington James are a Global specialist recruitment consul­tancy with offices in the UK, USA and Asia that work across the Healthcare sector.  Our structure, with separate divisions and dedicated consultants for the markets we serve ensures a thorough, professional and intelligent approach in both permanent and interim solutions.  Our tailored methodologies include Contingency database search and executive search.

Bavarian Nordic, Inc.

Bavarian Nordic, Inc. (Mountain View, CA) is the Cancer Immunotherapy Division of Bavarian Nordic (BN), a leading biotechnology company working to target unmet medical needs by developing and producing novel vaccines and cancer immunotherapies for prevention and treatment of life-threatening diseases. BN’s lead active immunotherapy candidate, PROSTVAC®, is currently in a Phase 3 pivotal trial for metastatic prostate cancer.

Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Bayer HealthCare Pharmaceuticals

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Biocartis

Biocartis strives to transform the global diagnostics market by providing instant access to personalized medicine to patients worldwide. Biocartis develops fully integrated and broadly applicable molecular diagnostics solutions for oncology and infectious diseases. Biocartis’ Idylla™ system is an easy to use, fully integrated MDx system with true sample-in, result-out functionality. 

Boehringer Ingelheim GmbH

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales. 

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis.

Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, a comprehensive tumour profiling service, provides oncologists with clinically actionable biomarker/drug associations to individualise care, using advanced technologies that assess relevant biological components of a patient’s cancer.

CeGaT GmbH

CeGaT is a genetic diagnostic laboratory that offers multiple panels for Tumor Diagnostics as well as the analysis of complete tumor exomes. By utilizing next generation sequencing technology, we sequence both tumor and control tissue to identify somatic mutations with highest sensitivity. Results are interpreted by our interdisciplinary team and summarized in a comprehensive medical report to support treatment decisions.

Celgene

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for cancer and other severe, immune, inflammatory conditions. Celgene employs more than 5,300 employees worldwide.

EXCEMED

EXCEMED is an independent, not-for profit organisation committed to improving the lives of patients through the provision of high impact medical education to scientists, physicians, nurses, pharmacists and other healthcare professionals. EXCEMED has a long standing tradition of delivering excellence in medical education all over the world. In its 40 year history, it has organized more than 1500 international scientific conferences with more than 500 proceedings appearing in leading international publications. The Foundation also provides online medical education via the EXCEMED  website and dedicated disease specific microsites.

Exelixis, Inc.

Exelixis® is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer.

F.Hoffmann-La Roche Ltd

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader inin vitrodiagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. 

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Fresenius Kabi Deutschland GmbH

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The products and services help to care for critically and chronically ill.
Product portfolio: I.V. generic drugs, infusion therapies, clinical nutrition and related medical devices, products for whole blood and blood components collection and processing, transfusion medicine and cell therapies.

Genomic Health

Genomic Health, Inc. is a world's leading provider of genomic-based diagnostic tests that inform treatment decisions and help to ensure each patient receives appropriate treatment for early stage cancer. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.

Global Oncology Academy

The Global Oncology Academy (GOA) is an educational program designed specifically for physicians and other healthcare professionals in the field of oncology. The GOA offers healthcare professionals a unique opportunity to participate in e-Learning modules, as well as stay abreast of the latest news and events. 

GSK

GSK is dedicated to the patients, physicians and communities pursuing the fight against cancer. At GSK, our portfolio of medicines represents a heritage spanning more than five decades. Whether you are a physician, researcher, or patient, we aspire to know how GSK might engage with you in fighting the global pandemic known as cancer.

Helsinn Group

Helsinn is a private pharmaceutical group focused on building quality cancer care headquartered in Switzerland with subsidiaries in Switzerland, Ireland, US, and representative office in China. Helsinn’s business model is focused on developing, registering and licensing pharmaceuticals, medical devices and nutritional supplements through partner companies, and marketing pharmaceutical products in the US through its subsidiary Helsinn Therapeutics (U.S.), Inc. 

Hospira

Hospira is the world’s leading provider of injectable generic drugs and infusion technologies. Through its broad integrated portfolio, Hospira is uniquely positioned to improve patient and caregiver safety whilst reducing healthcare costs.  Hospira offers a broad range of generic acute-care and oncology injectables, biosimilar medicines, integrated infusion therapy and medication management solutions.  The head office for Hospira in Europe, Middle East and Africa is in Royal Leamington Spa, UK.

Imedex, LLC

Imedex is dedicated to improving patient care through the education of medical professionals.  We develop high quality scientific activities that translate the latest research into clinically relevant information. Our established relationships with leading investigators and researchers and some of the world’s most prestigious societies make our educational offerings the most effective in the industry. 

Intrasense

Intrasense designs Myrian®, the ultimate imaging software suite in oncology. Dedicated to clinical research and patient care, Myrian® takes advantage of multiparametric and multimodal imaging. Key benefits are: efficient oncology workflow, improved tumor boards, time saving, standardized imaging endpoints for clinical trials through Structured Reading™ and validation of new imaging biomarkers.

IPSEN

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: urology-oncology, endocrinology and neurology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Ipsen also has a significant presence in primary care. 

Janssen

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).

Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. 

Keosys Medical Imaging

Specialized in clinical routine & clinical trials and established in France (Nantes), the USA (Philadelphia) and Singapore, KEOSYS positions itself as a major and global actor in medical imaging. Imagys is the reference in Cloud Clinical Trial Imaging Management System (CTIMS).

Thanks to its fully integrated reading workflow and its remote viewing system for tumor response evaluation (PET & CT segmentation, lesion tracking system, automatic calculation of the response), Keosys is the imaging partner to choose for your trials.

Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease.  Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon’s research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.

Lilly Oncology

For over four decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer.  Lilly Oncology is committed to developing novel treatment approaches, accelerating the pace and progress of cancer care.  We understand cancer care is complex and we’re working to provide support services that are meaningful for you and your patients.

MBL International Corporation (MBLI)

Established in 1993, MBL International Corporation (MBLI) is a leading life science company focused on providing high quality, innovative, solutions-based products for both life science research and clinical diagnostics. Our products are used widely in academic research institutions, pharmaceutical and biotechnology companies, government agencies as well as hospital and reference laboratories. MBLI develops, manufactures, and markets a broad portfolio of monoclonal and polyclonal antibodies, MHC tetramers, fluorescent and recombinant proteins and ELISA kits for research related to allergy, apoptosis, autophagy, cancer, epigenetics, immunology, and neuroscience.

Medac GmbH, Wedel Germany

Medac is specialised in the treatment of malignant diseases since its foundation in 1970. Now, medac is one of the leading manufacturers of oncology products not only in Germany, but in many international markets. Medac offers both, innovative and well proven, therapeutic options in the fields of Oncology, Hematology, Urology, Autoimmune diseases and Fibrinolysis and is one of a handful of companies which is also specialised in the field of diagnostics. 

MEDIAN Technologies

MEDIAN Technologies provides clinical trial imaging services to biopharma sponsors for oncology drug development. MEDIAN’s services span the full imaging process for Phase I to IV oncology clinical trials. MEDIAN is currently providing imaging services to Top 10 pharmaceutical companies and biotechnology companies. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America and Australia. 

Merck Serono

Merck Serono, a division of Merck KGaA, focuses its oncology research on the development of therapies that target the tumor cell directly, the tumor environment and/or the immune system. These include the monoclonal antibody Erbitux® (cetuximab) and the investigational compounds TH-302, a hypoxia-activated prodrug and tecemotide, a MUC1 antigen specific cancer immunotherapy.

MSD

Today's MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well.

Myriad Genetics GmbH

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

NanoString Technologies

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is FDA 510(k) cleared.

Nordic Pharma

The Nordic Group is a pan-European pharmaceutical company, with a strong focus on the development and commercialization of niche hospital and orphan products in 14 European countries. In addition, the Nordic Group specializes in product development, manufacturing, supply logistics, clinical studies and regulatory activities. 

Norgine

Founded in 1906, Norgine is a leading independent European specialty pharmaceutical company. In 2013, Norgine’s total revenue was €274 million and the company employs over 1,000 people. Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care.

Novartis Oncology

Novartis Oncology is a global leader in transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Novocure

Novocure Limited is a private oncology company developing and commercializing NovoTTF Therapy, a novel treatment for solid tumor cancers. Novocure Limited is registered in the Jersey Isle, with subsidiaries in the US, Europe, Israel and Japan. Novocure’s US operations are based in Portsmouth, NH and New York, NY. European operations are based in Switzerland and the company maintains a research center in Haifa, Israel.

Nutricia Advanced Medical Nutrition

Nutricia Advanced Medical Nutrition focuses on pioneering nutritional discoveries that help people live healthier and longer lives. It seeks to establish Advanced Nutrition as an integral part of healthcare. Nutricia's extensive range of nutrition products and services offer proven benefits and better clinical outcomes. The company works with doctors and healthcare professionals to deliver better care in more than 50 countries.

Ockham Oncology

Ockham has merged with Chiltern Oncology as the specialist division delivering expertise across all phases of oncology clinical development. Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in oncology and a range of other therapeutic areas, together with global sourcing and FSP solutions. Chiltern’s 2,100 people work in more than 40 countries and offer expertise, engagement and tailored responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.

OncoDNA SA

OncoDNA, The Cancer Theranostic Company, is a leading company specialized in the personalized analysis of tumor to improve cancer treatment choice. OncoDEEP provides genomic analysis (NGS) of actionable genes combined with classical IHCs to deliver oncologists with drug treatment recommendations. This report is available through a unique web interface called OncoSHARE which allows oncologist to share and discuss the results. 

OncoGenex

OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers. 

Oncotherm GmbH

Oncotherm develops and manufactures cancer treatment systems using a special kind of hyperthermia (Oncothermia) that is applied as complementary treatment to chemo- and radiotherapy. The method can be applied to all tumor types and stages. Treatment goals are the extension of the survival time, improvement of the quality of life and minimization of the side effects of chemo- and radiotherapy.

Otsuka Pharmaceutical Europe Ltd.

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: "Otsuka-people creating new products for better health worldwide."

Otsuka is committed to focusing its research and development on innovative products and medical devices that address unmet medical needs. Come and visit Otsuka Europe at Stand 143 to learn more about Otsuka’s commitment to innovation and education. 

Paxman

Paxman is the leading global manufacturer and supplier of scalp-cooling equipment. A family business borne from first-hand experience, Paxman understand the personal effects of chemotherapy-induced alopecia. With its revolutionary scalp-cooling system, Paxman is responsible for helping thousands of people worldwide and aim to ensure that patients, irrespective where, have opportunity to keep their hair, dignity and self-confidence throughout chemotherapy treatment.   

Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals is developing novel monoclonal antibodies focused on the treatment of cancer. Its phosphatidylserine (“PS”)-targeting platform has led to Peregrine’s lead immunotherapy candidate, bavituximab, being the subject of six ongoing oncology-focused clinical trials including the SUNRISE Phase III trial in second-line non-small lung cancer. Bavituximab is an upstream immune checkpoint inhibitor that has demonstrated important immuno-stimulatory changes in tumors. 

Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.

PHARMADAB D.O.O.

Pharmadab, a Pharmaceutical Engineering Company. Pharmadab is an innovative pharmaceutical company that produces medicine and medical devices the development of which is based on our own research. R&D is primarily oriented into supportive care for skin toxicity due to oncological treatments. Our two main products are:

  • Reconval K1 relieves skin problems caused by anti-cancer therapies
  • Reconval B6 hand-and-foot  syndrome and post-radiotherapy skin inflammation relief cream

PharmaMar (Zeltia Group)

PharmaMar (Zeltia Group) is a Spanish biopharmaceutical company committed to advancing the treatment of cancer through the discovery, development and commercialization of new marine-derived medicines.

PharmaMar’s Yondelis®, is the first anti-tumor drug developed by a Spanish company approved by the EMA. It is currently on the market for the treatment of advanced soft tissue sarcoma (STS) and relapsed ovarian cancer (ROC).

Pierre Fabre Medicament

Pierre Fabre is present in more than 140 countries worldwide. Our oncology products are Navelbine® Oral (oral vinorelbine) for the treatment of advanced breast cancer and non-small cell lung cancer, and Javlor® (vinflunine) for the treatment of advanced urothelial carcinoma after failure of a platinum containing regimen. Javlor® is currently under phase III development for the advanced breast cancer.

Pivotal

Pivotal is a leading one-stop shop offering CRO services to the healthcare industry. Our people are all bound by a shared passion for taking on the immense challenges of clinical development programmes with IMPs, medical devices, diagnostics and nutrition products. Our clients will enjoy the benefits of senior management hands-on environment, operational teams working on the ground with the clinical sites, deep therapeutic expertise and cost-effective deliverables. By applying a variety of outsourcing models from single source to full service, Pivotal builds a flexible client relationship, and ensures a single-source provider. We share our clients objectives and deliver a solid programme to achieve promising results.

prIME Oncology

prIME Oncology is a global, accredited, professional Independent Medical Education provider specializing in the development and implementation of innovative and clinically relevant educational activities for oncology healthcare professionals.

QIAGEN GmbH

QIAGEN, the leading global provider of Sample & Assay Technologies, enables access to content from any biological sample. QIAGEN markets more than 500 products worldwide, both consumable kits and automation systems to customer in Molecular Diagnostics, Applied Testing, Pharma and Academia.

Research to Practice

Research To Practice (RTP) is an ACCME-accredited provider of continuing medical education focused exclusively on oncology and hematology. Founded and led by medical oncologist, Neil Love, MD, RTP currently develops live, audio, print, Internet and interactive educational activities to meet the needs of oncology clinicians and positively impact the care of patients with cancer.

SANDOZ

Sandoz, a Novartis company, is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90% of the world’s population. Sandoz Biopharmaceuticals and Oncology Injectables, a specialized business within Sandoz, develops produces and markets high-quality and affordable biologics and oncology injectables. 

SIMBEC-ORION

ORION Clinical Services, a specialist oncology CRO, has merged with SIMBEC Research.  These long-established organisations share a heritage of quality, customer focus and cost-effectiveness. SIMBEC-ORION is a seamless, full service Phase I-IV CRO/Central Laboratory. 

With many years of oncology specialisation our Medics, CRAs, Project Managers, Regulatory Personnel and Laboratory Managers offer in-depth, hands-on experience of this complex therapeutic area

Sirtex Medical Europe GmbH

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.

Our innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was approved in 2002 for use in the treatment of a variety of unresectable liver tumours a well as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres® microspheres are presently used at more than 250 institutions in Europe.

®SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd.

SOTIO a.s.

SOTIO is an international biotechnology company developing new medical therapies, using platform of active cellular immunotherapy on the basis of dendritic cells and focusing on the treatment of cancer and autoimmunity diseases. SOTIO has active presence in Europe, the US, Russia and China and its own GMP cell therapy manufacturing and research facilities equipped with state-of-the-art technologies.

Sysmex

Sysmex, a global leader in diagnostic solutions, is developing and distributing advanced technologies to improve cancer treatment, such as DigniLife® for chemotherapy induced hair loss prevention and SentiMag® for sentinel node localisation without radiotracer. Sysmex Inostics is a leader in blood-based cell-free tumor DNA oncology testing services. The company also offers global services for pharmaceutical companies – from discovery to companion diagnostics.

Taiho Oncology, Inc.

Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.

Takeda

Headquartered in Osaka, Japan, Takeda is a research-based global pharmaceutical company. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health and a brighter future for patients worldwide through leading innovation in medicine.

Teva Pharmaceuticals Europe BV

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.

Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules.

Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices.

Xi'an Good Doctor Medical Science and Technology Co.,Ltd.

Xi'an Good Doctor Medical Science and Technology Co. is a leading company in manufacturing hyperthermic perfusion device, which is widely used for intra-body-cavity chemotherapy. This device is easily used in both surgical operation room and patient’s ward. It is used not only to treat malignant effusion, but also to prevent cancer recurrence following complete cytoreductive surgery.